Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 16/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.78 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluprostenol SCHEMBL16414486 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL16414497 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL2744986 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL10015915 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342036 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL13260302 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342073 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL6750653 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL20860290 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL3364535 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2235 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | ALCON INC (CH) | 2026-02-05 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| WO-2024091572-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | VERADERMICS INCORPORATED (US) | 2024-05-02 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230094779-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTICS AGENTS | NOVAER HOLDINGS INC (US) | 2023-03-30 | — | — | US | claimed |
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| US-11413309-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | claimed |
| US-20220088000-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2022-03-24 | — | — | US | claimed |
| EP-3934646-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | Aerie Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | claimed |
| CN-113784727-A | Pharmaceutical compositions for treating ocular diseases or disorders | 爱瑞制药公司 | 2021-12-10 | — | — | CN | claimed |
| EP-0664707-B1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LAB INC (US) | 1997-06-04 | — | — | EP | claimed |
| US-5605922-A | VISION DISORDERS; SIDE EFFECT REDUCTION | ALCON LABORATORIES, INC. (US) | 1997-02-25 | — | — | US | claimed |
| US-5565492-A | Prostaglandin combinations in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1996-10-15 | — | — | US | claimed |
| WO-1996013267-A2 | COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF FOR THE TREATMENT OF GLAUCOMA | ALLERGAN (US) | 1996-05-09 | — | — | WO | claimed |
| US-5480900-A | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma | ALCON LABORATORIES, INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0664707-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA. | ALCON LAB INC (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0639563-A2 | Use of cloprostenol, fluprostenol and their analogues for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension | ALCON LABORATORIES, INC. (US) | 1995-02-22 | — | — | EP | claimed |
| US-5369128-A | Administering a prostaglandin and a peripheral A2 adrenergic agonist | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1994-11-29 | — | — | US | claimed |
| EP-0603800-A1 | Prostaglandin combinations in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1994-06-29 | — | — | EP | claimed |
| WO-1994008585-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1994-04-28 | — | — | WO | claimed |